Today’s pharmacovigilance (PV) teams face mounting pressure to analyze increasingly larger volumes of safety data while meeting progressively complex global reporting expectations. According to Deloitte’s 2026 Life Sciences Outlook, 48% of life sciences executives say the rapid adoption of digital technologies and data analytics will substantially impact their organizations. Another area of growing interest is…
Scaling pharma AI PoCs to enterprise deployments: Blending new tech with old-school rigor
Scalability is a common issue facing pharma leaders who have deployed Generative AI (GenAI) applications as a proof of concept (PoC). Many are dazzled by their promise of streamlining staid work processes. Agentic AI and other new GenAI technologies can make PoCs faster and easier to launch, advancing scalability as well as security and development…

